P-089FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial
Fernández Montes, A, Martinez Lago, N, De la Cámara Gómez, J, Covela Rúa, M, Cousillas Castiñeiras, A, Gonzalez Villarroel, P, Méndez Méndez, JVolume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz155.088
Date:
July, 2019
File:
PDF, 85 KB
english, 2019